Target intelligence / Profile preview

Cholesterol absorption pathway

Molecular classification
Other (biological pathway), Transporter (key molecular components include specific transporters such as Niemann-Pick C1-like 1 protein)
01

Overview

The **cholesterol absorption pathway** refers to the multistep biological process by which dietary and biliary cholesterol is absorbed from the intestinal lumen into enterocytes and subsequently transported into circulation. The key molecular mediator is **Niemann-Pick C1-like 1 protein (NPC1L1)**, a transmembrane transporter highly expressed on the brush border membrane of small intestinal epithelial cells. Free cholesterol from micelles interacts with NPC1L1 for uptake into enterocytes. Once inside, it is esterified by acyl-CoA:cholesterol acyltransferase (ACAT), packaged with triglycerides and apolipoprotein B48 into chylomicrons via microsomal triglyceride transfer protein (MTP), then secreted into lymphatics for systemic distribution. Efflux back to the gut lumen is mediated by ATP-binding cassette transporters ABCG5/ABCG8[2][4][6][8]. This process regulates whole-body cholesterol homeostasis and plays a central role in cardiovascular risk; pharmacologic inhibition of this pathway—most notably by ezetimibe—reduces plasma LDL-cholesterol levels. "Cholesterol absorption pathway" describes a **biological process**, not a single molecule or receptor. The actual therapeutic targets within this pathway are specific proteins such as **NPC1L1** or ABCG5/ABCG8; thus, listing "Cholesterol absorption pathway" as a target is incorrect—it should be replaced with one or more precise molecular entities like "Niemann-Pick C1-like 1 protein"[2][4][6][8].

Other names
Intestinal cholesterol absorptionCholesterol uptake pathwayNPC1L1-mediated cholesterol transportEnterocyte cholesterol transport
02

Mechanism of action

Inhibition of intestinal cholesterol transporter NPC1L1 to reduce dietary and biliary cholesterol absorption

03

Biological functions

Lipid absorptionNutrient uptakeRegulation of plasma cholesterol levelsMaintenance of cellular membrane composition
04

Disease associations

Cardiovascular diseaseHypercholesterolemiaAtherosclerosisMetabolic syndrome
05

Safety considerations

Malabsorption syndromes with excessive inhibition or genetic defects in the pathway
06

Interacting drugs

Ezetimibe (inhibits NPC1L1)

1 more in the full profile.

07

Biomarkers

Plasma LDL-cholesterol levels

Beyond the preview

Go deeper on Cholesterol absorption pathway.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cholesterol absorption pathway.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call